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Background: Painful ophthalmoplegia with normal cranial imaging is rare and confined to limited etiologies. In this
study, we aimed to elucidate these causes by evaluating clinical presentations and treatment responses.
Methods: Cases of painful ophthalmoplegia with normal cranial MRI at a single center between January 2001 and
June 2011 were retrospectively reviewed. Diagnoses of painful ophthalmoplegia were made according to the
recommendations of the International Headache Society.
Results: Of the 58 painful ophthalmoplegia cases (53 patients), 26 (44.8%) were diagnosed as ocular diabetic
neuropathy, 27 (46.6%) as benign Tolosa-Hunt syndrome (THS), and 5 (8.6%) as ophthalmoplegic migraine (OM).
Patients with ocular diabetic neuropathy were significantly older (62.8 ± 7.8 years) than those with benign THS
(56.3 ±12.0 years) or OM (45.8 ± 23.0 years) (p < 0.05). Cranial nerve involvement was similar among groups. Pupil
sparing was dominant in each group. Patients with benign THS and OM responded exquisitely to glucocorticoid
treatment with resolved diplopia, whereas patients with ocular diabetic neuropathy didn’t (p < 0.05). Patients with OM
recovered more rapidly than the other groups did (p < 0.05). Overall, most patients (94.8%) recovered completely during
the follow-up period.
Conclusions: Ocular diabetic neuropathy and benign THS accounted for most of the painful ophthalmoplegias in
patients with normal cranial imaging. Patient outcomes were generally good.
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Painful ophthalmoplegia consists of periorbital or hemi-
cranial pain with ipsilateral ocular motor nerve palsies
[1]. The syndrome involves diverse causes; therefore, a
comprehensive evaluation is essential. Contrast-enhanced
magnetic resonance imaging (MRI) provides sensitive
detection of structural abnormalities, such as trauma,
infection, malignancy, or vascular anomaly [2,3].
However, neuroimaging studies frequently yield nega-
tive findings in patients with painful ophthalmoplegia
[4]. Cranial neuropathies in diabetic patients due to* Correspondence: cgrols@adm.cgmh.org.tw
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reproduction in any medium, provided the ormicrovasculopathy occasionally demonstrate painful oph-
thalmoplegia with normal neuroimaging studies [5,6].
Maintaining optimal glycemic control may aid recovery [5].
Ophthalmoplegic migraine (OM), which frequently occurs
in childhood [7], may also present as painful ophthalmo-
plegia in adulthood upon normal imaging studies [8].
The use of glucocorticoids along with migraine prophy-
laxes, such as β-blockers or calcium channel blockers,
may hasten recovery [8]. Occasionally, idiopathic inflam-
mation of the cavernous sinus (CS) can cause painful oph-
thalmoplegia. Tolosa-Hunt syndrome (THS) is caused by
an inflammatory process of unknown etiology. Although
granulomatous tissues in the CS can often be identified in
these patients (referred to as inflammatory THS), half of
the patients with clinical presentation and diagnosis of
THS have no radiographic evidence of inflammation
[9,10]. The eponym “benign THS” has been introducedtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[9]. Glucocorticoids are considered as standard treatment
for patients with THS [1,10].
Given that the choice of treatment depends on an ac-
curate diagnosis, it is essential to understand the clinical
presentations in patients with MRI-negative painful oph-
thalmoplegia. In this study, we aimed to elucidate the
causes in this group of patients by evaluating their clin-
ical presentations and responses to treatment. These re-
sults will be important for guiding appropriate treatment
decisions in patients with painful ophthalmoplegia.
Methods
Consecutive adult patients referred with painful ophthal-
moplegia to Chang Gung Memorial Hospital were col-
lected from January 2001 to June 2011. Their in-hospital
medical chart records were retrospectively reviewed with
approval of the Institutional Review Board of the Chang
Gung Memorial Hospital (license ID: 100-0136B). Patients
who developed periorbital or hemicranial pain combined
with ipsilateral oculomotor, trochlear, and/or abducent
palsies were recruited in this study. All patients had appro-
priate laboratory workup, including complete hematologic
and routine tests, electrolytes, renal and liver function test,
anti-nuclear antibody, thyroid function, C-reactive protein,
elevated sedimentation rate (ESR), fasting glucose, and gly-
cohemoglobin (HbA1c). All recruited patients also under-
went cranial MRI and cerebral vascular investigations (MR
angiography or digital subtraction angiography). None
of the patients had concurrent infection, malignancy,
Sjögren’s syndrome, systemic lupus erythematosus, rheu-
matoid arthritis, vasculitis, cranial herpes zoster, Horton
arteritis, or immunocompromised status.
The diagnosis of painful ophthalmoplegia was made
according to the recommendations of the International
Headache Society (IHS), 2nd edition (ICDH-2) [4]. Patients
with diabetes (fasting plasma glucose ≥ 126 mg/dL or
HbA1c ≥ 6.5%) developing painful ophthalmoplegia with-
out other attribution after workup were designated as ocu-
lar diabetic neuropathy [4,11]. Patients with idiopathic
unilateral painful ophthalmoplegia fulfilling the IHS criteria
for THS and with normal cranial imaging were designated
as benign THS [9]. Since THS symptoms may resolve
spontaneously when left untreated [1,10,12], patients with
idiopathic painful ophthalmoplegia fulfilled THS criteria
(A, B and C) and self-remission within 3 months were also
considered as those with THS. These patients with THS
may have delayed diplopia improvement after 6–8 weeks
of glucocorticoid treatment [13]; therefore, patients fulfill-
ing the THS criteria with pain resolving within 72 hours
after treatment, but without immediate improvement
in their diplopia, were also allocated to the THS
group. Patients with migrainous headache accompan-
ied or followed by ophthalmoplegia within 4 days inaccordance with the IHS criteria for OM was allo-
cated to the OM group [4]. Patients with a single at-
tack fulfilling the OM criteria were also considered as
having OM [8,14]. All enrolled patients underwent a
follow-up period of at least 6 months to ensure no
other etiology was identified.
All enrolled patients underwent cranial MRI with a
standard head coil on a 1.5- to 3-T MR scanner. The
predefined MR scan parameters used in this study were
as follows: TR = 450–550 ms, TE = 9.9–12 ms, field of
view (FOV) = 200 × 200 mm, and matrix = 512 × 512 in
transverse and coronal T1-weighted spin-echo sequences
before and after intravenous administration of gadolinium
enhancement (0.2 ml/kg); TR = 3114–4000 ms, TE = 81–
90 ms, FOV = 200 × 200 mm, matrix = 512 × 512 in trans-
verse T2 fast spin-echo sequence; and TR = 6000–9000,
TE = 105–142 ms, FOV = 200 × 200 mm, and matrix =
512 × 512 for transverse fluid-attenuated inversion recov-
ery sequence (FLAIR). Sections were either 3 or 5 mm
in thickness. Cerebral vascular investigations, including
MR angiography or digital subtraction angiography,
were performed in all recruited patients to exclude vas-
cular anomalies.
Cranial scans of painful ophthalmoplegias were indi-
vidually and retrospectively reviewed, by 2 experienced
neuroradiologists (Wu, YM and Chen, YL) with a focus
on the parasellar area and orbits. Both reviewers were
aware of the symptom of painful ophthalmoplegia but
were blind to the final diagnosis. Only cases with normal
neuroimaging findings, consented by both reviewers, were
further analyzed.
Glucocorticoid dosages and response to treatment were
registered. A positive response to glucocorticoids was
defined as relief of symptoms or improved neurologic
signs within 3 days of glucocorticoid treatment initi-
ation [4,15,16].
Statistical analyses were performed using SPSS statis-
tical software (version 17.0, Chicago, IL, USA). Descrip-
tive statistics were expressed mean ± standard deviation
(SD) for continuous data, whereas the number with its
percentage for categorical data. Continuous variables were
compared using Kruskal Wallis tests followed by post-hoc
Dunn tests if statistically significant. Categorical variables
were compared using chi-square test. Disease course was
estimated according to the Kaplan-Meier method. The
endpoint of the primary study was the time until complete
resolution of symptoms and signs. All p values were two-
tailed. In all tests, p < 0.05 was considered statistically
significant.
Results
There were 121 referrals with symptomatic diagnoses of
unilateral painful ophthalmoplegia (Figure 1). Four pa-
tients were excluded because of incomplete neuroimaging
Figure 1 Flow chart illustrating the diagnostic process of painful
ophthalmoplegias with normal cranial imaging and the diagnostic
outcome after investigation. (Abbreviations: PO = painful
ophthalmoplegia; DM= diabetes mellitus; FPG = fasting plasma glucose;
HbA1C = glycohemoglobin; THS = Tolosa-Hunt syndrome).
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117 patients, 54 patients with radiographic evidence of
cranial lesions were excluded because of the following
conditions: carotid-cavernous fistula (10 patients), P-com
aneurysm (2 patients), primary head and neck neoplasms
(6 patients), primary intracranial neoplasm (3 patients),
cavernous sinus metastases (2 patients), sinonasal infection
(5 patients), orbital infection (4 patients), trauma (1 pa-
tient), and idiopathic inflammatory Tolosa-Hunt syndrome
(21 patients). Ten patients with initial normal neuroimag-
ing were also excluded because of the lack of follow-up. Fi-
nally, 53 qualified patients with normal neuroimaging data
were recruited for this study. Twenty-five patients (47.2%)
were diagnosed as having ocular diabetic neuropathy, and
25 (47.2%) and 3 (5.7%) patients were diagnosed with
benign THS and OM, respectively (Table 1). Recurrent
episodes were reported in 1 patient (4.0%) with ocular
diabetic neuropathy, 1 patient (33%) with OM, and 2 pa-
tients (8.0%) with benign THS. A total of 58 episodes
were recruited for further analysis.
Demographic data and clinical presentations between
the groups are summarized in Table 1. Patients with ocular
diabetic neuropathy were significantly older than patients
with benign THS (post-hoc tests; p = 0.045) and patients
with OM (p = 0.004) (Table 1). All patients with diabeticophthalmoplegia had type II diabetes mellitus (DM), and
the known duration of diabetes was 9.9 ± 9.4 years. Five
patients (20.0%) were newly diagnosed with DM. No pa-
tient with final diagnosis of THS or OM had diabetes or
impaired fasting glucose. All patients with OM had adult-
onset migrainous headache.
Cranial nerve involvement was not significantly different
among groups (Table 1). The most frequently involved
cranial nerve was the oculomotor nerve in all groups
(74.1%), followed by the trochlear nerve (53.4%) and the
abducens nerve (39.7%). Pupillary function was not altered
in most patients; pupil sparing was common in patients
with ocular diabetic neuropathy as well as in other groups.
Compared to patients with diabetic ophthalmoplegia,
those with benign THS and OM were prone to multiple
ocular motor neuropathies, even though there was no sig-
nificant difference among groups.
In the laboratory examinations, the ESR was not sig-
nificantly different within groups. Anti-nuclear antibody
(ANA) and rheumatoid factor (RF) were also non-specific.
Compared to benign THS (5.9 ± 2.5%) and OM (6.2 ±
0.6%), ocular diabetic neuropathy was associated with
higher levels of glycohemoglobin (8.4 ± 1.8%, p = 0.003).
All enrolled patients underwent a follow-up period of
at least 6 months to ensure no other etiology was identi-
fied. The mean duration from initial symptoms to the
last follow-up was 3.4, 4.9, and 3.6 years in patients with
ocular diabetic neuropathy, benign THS, and OM, re-
spectively. No patients had newly diagnosed autoimmune
disease, intracranial malignancy, vascular malformation,
sarcoidosis, central nervous system (CNS) infection, or
HIV infection during the follow-up period.
The duration from onset to complete recovery in ocu-
lar diabetic neuropathy was 2.0 ± 1.0 months, which was
similar to that in benign THS (1.6 ± 0.8 months). Recovery
was significantly more rapid (0.9 ± 0.4 months) in OM
than either in benign THS or in ocular diabetic neur-
opathy (log-rank test, p = 0.005, Figure 2). In most cases
(n = 55, 94.8%), patients reported complete recovery within
3 months, except for 1 case of benign THS (3.7%) and 2
cases of ocular diabetic neuropathy (8.3%) with minor se-
quelae of diplopia.
Glucocorticoids were prescribed in 24 episodes (88.9%)
of benign THS and 4 of OM (80.0%). Therapeutic trial of
glucocorticoids was used in 13 episodes (50.0%) of ocular
diabetic neuropathy because of initially inconclusive diag-
noses. Four patients with benign THS and 2 patients with
ocular diabetic neuropathy improved before glucocortic-
oid use and, thus, were excluded from these analyses. The
mean dose of prednisolone was 1.3 ± 3.7 mg/kg/day.
Immediate pain relief within 72 hours of treatment was
observed in nearly all patients. Regarding resolved diplo-
pia, patients with benign THS and OM responded well to
glucocorticoids (95.0% and 100.0%, respectively), but only
Table 1 Demographic data and clinical manifestations of painful ophthalmoplegia with normal neuroimaging
Ocular diabetic neuropathy Benign Tolosa-Hunt syndrome Ophthalmoplegic migraine Total p value
N (%) 25 (47.2) 25 (47.2) 3 (5.7 ) 53
N of episodes 26 27 5 58
M/F 12/13 10/15 3/0 25/28
Age (year) 62.8 ± 7.8 56.3 ± 12.0 45.8 ±23.0 58.3 ± 12.4 0.008*
Involvement of cranial nerves, N (%)
CN3 19 (73.1) 20 (74.1) 4 (80.0) 43 (74.1) 0.949
CN4 9 (34.6) 15 (55.6) 2 (40.0) 23 (39.7) 0.301
CN6 13 (50.0) 16 (59.3) 2 (40.0) 31 (53.4) 0.652
Ptosis 16 (61.5) 11 (40.7) 1 (20.0) 28 (48.3) 0.132
Pupillary dysfunction 7 (26.9) 6 (22.2) 0 (0.0) 13 (22.4) 0.417
Multiple CNs involvement 10 (38.5) 18 (66.7) 3 (60.0) 31 (53.4) 0.115
Laboratory data
ESR (mm/hr) 29.4.2 ± 28.0 14.2 ± 21.7 9.6 ± 8.4 0.070
HbA1c (%) 8.3 ± 1.8 5.9 ± 2.5 6.2 ± 0.6 0.003*
Recurrence, N of patients (%) 1 (4.0) 2 (8.0) 1 (33.3) 0.190
Duration of course (month) 2.0 ± 1.0 1.6 ± 0.8 0.9 ± 0.4 1.7 ± 0.9 0.044*
Duration of follow-up (year) 3.4 ± 3.1 4.9 ± 3.6 3.6 ± 0.3 4.0 ± 3.3
Total recovery, N (%) 24 (92.3) 26 (96.3) 5 (100.0) 55 (94.8) 0.695
Symbols and abbreviations: N number; CN cranial nerve; ESR elevated sedimentation rate; HbA1c glycohemoglobin. Footnotes: * = statistically significant value.
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did so (p = 0.040, Table 2).
Discussion
The current study has several findings. Benign THS and
ocular diabetic neuropathy accounted for the majority ofFigure 2 The clinical courses of ocular diabetic neuropathy, benign T
are illustrated. The primary study endpoint was the time to complete reso
differed among these groups (Log-rank test, p = 0.005). OM (mean = 0.91 m
(mean = 1.64 months) and ocular diabetic neuropathy (mean = 1.99 monthcases of painful ophthalmoplegia with normal cranial im-
aging (91.4%). Clinical presentations were similar between
the groups, except for the age of onset, response to gluco-
corticoids, and duration of disease course. Nearly all pa-
tients with benign THS and OM had an immediate
improvement in ocular motor function after initiation ofolosa-Hunt syndrome (THS), and ophthalmoplegic migraine (OM)
lution of painful ophthalmoplegia. The duration of clinical course
onths) showed a significantly more rapid recovery than benign THS
s). Overall, most of the patients recovered completely (94.8%).
Table 2 Response rate of pain and diplopia to glucocorticoids in cases of painful ophthalmoplegia with
normal neuroimaging
Response to glucocorticoids Ocular diabetic neuropathy Benign Tolosa-Hunt syndrome Ophthalmoplegic migraine Total p value
Pain, N (%) 10 (90.9) 20 (100.0) 4 (100.0) 34 (97.1) 0.325
Diplopia, N (%) 7 (63.6) 19 (95.0) 4 (100.0) 30 (85.7) 0.040
A positive response to glucocorticoids was defined as relief of symptoms or improvement of neurologic signs within 3 days of glucocorticoid treatment.
MRI = magnetic resonance imaging; N = number.
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diabetic ophthalmoplegia did so. Patients with OM recov-
ered more rapidly than the other groups did. Overall, most
patients recovered completely during the follow-up period.
Patients with ocular diabetic neuropathy were signifi-
cantly older than patients with benign THS and OM. This
result is in accordance with previous reports; the mean re-
ported age of diabetic ophthalmoplegias ranges from 50.2
to 68 years [6,17-19], which is more than that of benign
THS (48.6 years) and adult OM (36.4 years) [8,9]. Diabetic
neuropathy is predominantly a disease of older adults [20],
whereas OM predominantly affects children and younger
adults [7,8], and THS may present at any age [1,9].
Glucocorticoid administration is of therapeutic and par-
tial diagnostic utility. The response of diplopia resolving
was of higher diagnostic value than that of pain relieving.
Orbital pain was dramatically relieved after glucocorticoid
treatment in almost all patients. Regarding diplopia resolv-
ing, only THS and OM respond exquisitely to glucocortic-
oid therapy [1,7] The immediate improvement of ocular
motor nerve dysfunction might reflect the inflammatory
pathogenesis of these diseases [7,12,21,22]. In contrast, is-
chemic pathogenesis associated with ocular diabetic neur-
opathy [5,23,24] decreases the response to glucocorticoids,
even though glucocorticoids can partially relieve pain
caused by ischemic injury.
Patients with OM recovered faster than patients with
THS and ocular diabetic neuropathy, consistent with pre-
viously reported results [7,10,18,19,25,26]. The average re-
covery time of OM is approximately 3 weeks, whereas
that of THS is approximately 2 months and ocular dia-
betic neuropathy is 3–4 months [7,9,10,18,19]. Although
the disease course varied among groups, the outcomes
were generally good. In our experience, most patients re-
covered completely within 3 months. Physicians should be
more vigilant if a patient fails to improve within 3 months,
and further aggressive investigation may be indicated.
Pupil sparing was not only common in patients with
ocular diabetic neuropathy, but was also common in
patients with THS and OM. It is widely accepted that
pupillary dysfunction is suggestive of aneurysmal or
neoplastic compressive lesions [27,28], and it is not
common in diabetic ophthalmoplegia [25,26,29]. Only
14–18% of patients with diabetic ophthalmoplegia develop
pupillary dysfunction [29]. In addition, the pupil is occa-
sionally affected in THS [4]. Although a majority of childpatients with OM have pupillary involvement [7], adult
patients with OMs tend to spare pupillary response [8].
Pupil sparing can be used as a potential marker for differ-
entiating these ophthalmoplegias from those caused by
structural compressive lesions.
Occasional reports have documented an elevated ESR in
the acute stage of THS [1]. However, there is no convincing
evidence for a correlation between connective tissue disease
and THS. In our study, the ESR results were grossly normal
in patients with benign THS. Therefore, ESR is of no diag-
nostic value in differentiating THS from other causes.
In the past, the absence of radiographic evidence of
inflammation in patients with THS was confusing to cli-
nicians, and a diagnosis of “idiopathic painful ophthal-
moplegia” was applied to these patients [30-32]. The
eponym of “benign THS” was first introduced by La Mantia
et al. in 2006 to describe these patients [9]. According to
the review by La Mantia et al., half of the THS patients
manifest as benign condition. Given the nosography of be-
nign THS has been proposed for less than a decade, it is
probable that such cases will continue to be diagnosed. The
exact proportion of benign and inflammatory cases remains
to be determined. A strong similarity between benign and
inflammatory THS was recently identified, and inflamma-
tion may contribute to the pathogenesis of both conditions
[10]. An official definition and elaboration of benign THS is
essential for clinical practice.
Painful ophthalmoplegia usually mandates an extensive
systemic workup for an underlying neoplastic, inflamma-
tory, infective or autoimmune disease. Because of the limi-
tations of a retrospective study, an exhaustive checkup for
screening was not possible. However, all recruited patients
had ancillary laboratory workup, cranial MR imaging, and
cerebral vascular investigation. In addition, none of the
patients had newly diagnosed malignancies, autoimmune
disease, or CNS infection during the follow-up period. Fur-
thermore, the results were generally favorable during the
follow-up period and all patients completely recovered or
experienced minor sequelae. Therefore, after the follow-up,
we could conclude that other causes of painful ophthalmo-
plegia were less likely and further confirmed the suitability
of our diagnoses.
In this study, the classification was based on the
ICHD-2 criteria and clinical specificity of each disease.
Patients with definite diabetes (fasting plasma glucose ≥
126 mg/dL or HbA1c ≥ 6.5%) were designated as ocular
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ate ocular diabetic neuropathy from benign THS comor-
bid with diabetes or impaired glucose tolerance at this
present technological stage. The limitation of the diagnos-
tic criteria might lead to selection bias in the classification.
Diabetic neuropathy may manifest before the diagnosis
of DM [5]. It is possible that patients manifesting oph-
thalmoplegia with undiagnosed DM could be mistaken as
those with THS. However, diabetic cranial neuropathies
mainly occur in older individuals with a long duration
of diabetes (mean = 8.5 ~ 16 years) [6,17,19]; an occult
diagnosis of diabetes is very less likely at this stage. In
addition, none of the THS or OM patients in this study
had a diagnosis of diabetes mellitus (fasting plasma glu-
cose ≥ 126 mg/dL or HbA1c ≥ 6.5%) or impaired fasting
glucose (fasting plasma glucose ≥ 100 mg/dL) [11]. Due
to the limitation of a retrospective study, the data of im-
paired glucose tolerance (IGT), tested by oral glucose
tolerance test, were incomplete in THS patients. Further
prospective studies are warranted to clarify the relation-
ship of benign THS and glucose intolerance.
Our study also had other limitations. First, the sample
size of each group, especially the OM group, might be too
small for adequate comparisons. Second, the conclusion
that steroid is of partial diagnostic utility might result from
the selection bias caused by the diagnostic criteria. Third,
the retrospective analysis limited our ability to collect
detailed information, forcing a reliance on documented
findings of examinations. Fourth, histological examina-
tions for pathological diagnoses lacked. Nevertheless, this
study provides useful information about the clinical fea-
tures of painful ophthalmoplegia and may warrant large-
scale prospective studies to assess the optimal treatment
approach.Conclusions
In summary, ocular diabetic neuropathy and benign THS
account for most of the painful ophthalmoplegias in pa-
tients with normal cranial imaging. Glucocorticoid admin-
istration is of therapeutic and partial diagnostic utility
because THS and OM respond exquisitely to the treat-
ment. Patients with OM recover more rapidly than the
other groups do. Patient outcomes are generally good.Consent
The Institutional Review Boards of the Chang Gung
Memorial Hospital waived the need for individual informed
consent because all data were anonymized and de-identified
prior to analysis.Competing interests
The authors declare that there is no conflict of interests.Authors’ contributions
CH: acquisition, analysis and interpretation of data, drafting the manuscript.
KC: analysis and interpretation of data. CC, ML, HC, RL and CL: substantial
contributions to conception and design. YW and YC: reviewing and
evaluating cranial images. HT: interpretation of data. LR: revising manuscript
critically for important intellectual content. All authors read and approved
the final manuscript.
Acknowledgements
We thank all the patients who participated in this study.
Author details
1Department of Neurology, Kaohsiung Municipal Hsiaokang Hospital,
Kaohsiung, Taiwan. 2Department of Neurology, Kaohsiung Medical University
Chung-Ho Memorial Hospital; Kaohsiung Medical University, Kaohsiung,
Taiwan. 3Department of Neurology, Linkou Campus, Chang Gung Memorial
Hospital and University College of Medicine, Gueishan Township, Taiwan.
4Department of Radiology, Linkou Campus, Chang Gung Memorial Hospital
and University College of Medicine, Gueishan Township, Taiwan.
5Department of Radiology, Keelung campus, Chang Gung Memorial Hospital
and University College of Medicine, Keelung City, Taiwan. 6Biostatistical
Center for Clinical Research, Chang Gung Memorial Hospital, Gueishan
Township, Taiwan.
Received: 16 July 2013 Accepted: 7 January 2014
Published: 9 January 2014
Reference
1. Kline LB, Hoyt WF: The Tolosa-Hunt syndrome. J Neurol Neurosurg
Psychiatry 2001, 71(5):577–582.
2. Wu HC, Ro LS, Chen CJ, Chen ST, Lee TH, Chen YC, Chen CM: Isolated
ocular motor nerve palsy in dural carotid-cavernous sinus fistula.
Eur J Neurol 2006, 13(11):1221–1225.
3. Huston J 3rd, Nichols DA, Luetmer PH, Goodwin JT, Meyer FB, Wiebers DO,
Weaver AL: Blinded prospective evaluation of sensitivity of MR
angiography to known intracranial aneurysms: importance of aneurysm
size. AJNR Am J Neuroradiol 1994, 15(9):1607–1614.
4. Headache Classification Subcommittee of the International Headache S:
The international classification of headache disorders. Cephalalgia 2004,
24(1):9–160.
5. Boulton AJ, Malik RA, Arezzo JC, Sosenko JM: Diabetic somatic
neuropathies. Diabetes Care 2004, 27(6):1458–1486.
6. Watanabe K, Hagura R, Akanuma Y, Takasu T, Kajinuma H, Kuzuya N, Irie M:
Characteristics of cranial nerve palsies in diabetic patients. Diabetes Res
Clin Pract 1990, 10(1):19–27.
7. McMillan HJ, Keene DL, Jacob P, Humphreys P: Ophthalmoplegic migraine:
inflammatory neuropathy with secondary migraine? Can J Neurol Sci
2007, 34(3):349–355.
8. Lal V, Sahota P, Singh P, Gupta A, Prabhakar S: Ophthalmoplegia with
migraine in adults: is it ophthalmoplegic migraine? Headache 2009,
49(6):838–850.
9. La Mantia L, Curone M, Rapoport AM, Bussone G, International Headache S:
Tolosa-Hunt syndrome: critical literature review based on IHS 2004
criteria. Cephalalgia 2006, 26(7):772–781.
10. Hung CH, Chang KH, Wu YM, Chen YL, Lyu RK, Chang HS, Wu YR, Chen CM,
Huang CC, Chu CC, et al: A comparison of benign and inflammatory
manifestations of Tolosa-Hunt syndrome. Cephalalgia 2013, 33(10):842–852.
11. American Diabetes A: Standards of medical care in diabetes–2011.
Diabetes Care 2011, 34(Suppl 1):S11–S61.
12. Hunt WE, Meagher JN, Lefever HE, Zeman W: Painful opthalmoplegia. Its
relation to indolent inflammation of the carvernous sinus. Neurology
1961, 11:56–62.
13. Cakirer S: MRI findings in Tolosa-Hunt syndrome before and after
systemic corticosteroid therapy. Eur J Radiol 2003, 45(2):83–90.
14. Giraud P, Valade D, Lanteri-Minet M, Donnet A, Geraud G, Guegan-Massardier E:
Is migraine with cranial nerve palsy an ophthalmoplegic migraine?
J Headache Pain 2007, 8(2):119–122.
15. Smith JL, Taxdal DS: Painful ophthalmoplegia. The Tolosa-Hunt syndrome.
Am J Ophthalmol 1966, 61(6):1466–1472.
16. Colnaghi S, Versino M, Marchioni E, Pichiecchio A, Bastianello S, Cosi V,
Nappi G: ICHD-II diagnostic criteria for Tolosa–Hunt syndrome in
Hung et al. BMC Neurology 2014, 14:7 Page 7 of 7
http://www.biomedcentral.com/1471-2377/14/7idiopathic inflammatory syndromes of the orbit and/or the cavernous
sinus. Cephalalgia 2008, 28(6):577–584.
17. Greco D, Gambina F, Maggio F: Ophthalmoplegia in diabetes mellitus: a
retrospective study. Acta Diabetol 2009, 46(1):23–26.
18. Jacobson DM: Pupil involvement in patients with diabetes-associated
oculomotor nerve palsy. Arch Ophthalmol 1998, 116(6):723–727.
19. Acaroglu G, Akinci A, Zilelioglu O: Retinopathy in patients with diabetic
ophthalmoplegia. Ophthalmologica 2008, 222(4):225–228.
20. Aaberg ML, Burch DM, Hud ZR, Zacharias MP: Gender differences in the
onset of diabetic neuropathy. J Diabetes Complications 2008, 22(2):83–87.
21. Tolosa E: Periarteritic lesions of the carotid siphon with the clinical
features of a carotid infraclinoidal aneurysm. J Neurol Neurosurg Psychiatry
1954, 17(4):300–302.
22. Carlow TJ: Oculomotor ophthalmoplegic migraine: is it really migraine?
J Neuroophthalmol 2002, 22(3):215–221.
23. Asbury AK, Aldredge H, Hershberg R, Fisher CM: Oculomotor palsy in
diabetes mellitus: a clinico-pathological study. Brain 1970, 93(3):555–566.
24. Smith BE, Dyck PJ: Subclinical histopathological changes in the
oculomotor nerve in diabetes mellitus. Ann Neurol 1992, 32(3):376–385.
25. Tesfaye S: Diabetic neuropathy: achieving best practice. Br J Diabetes Vasc
Dis 2003, 3(2):112–117.
26. Leslie D, Ellis C: Clinical course following diabetic ocular palsy.
Postgrad Med J 1978, 54(638):791–792.
27. Kissel JT, Burde RM, Klingele TG, Zeiger HE: Pupil-sparing oculomotor
palsies with internal carotid-posterior communicating artery aneurysms.
Ann Neurol 1983, 13(2):149–154.
28. Keane JR: Aneurysms and third nerve palsies. Ann Neurol 1983,
14(6):696–697.
29. Goldstein JE, Cogan DG: Diabetic ophthalmoplegia with special reference
to the pupil. Arch Ophthalmol 1960, 64:592–600.
30. Nieri A, Bazan R, Almeida L, Rocha FC, Raffin CN, Bigal ME, Schelp AO:
Bilateral painful idiopathic ophthalmoplegia: a case report. Headache
2007, 47(6):848–851.
31. Berthier E, Vighetto A, Aimard G, Confavreux C, Trillet M: Idiopathic cranial
polyneuropathies. Rev Neurol 1992, 148(1):20–23.
32. Foerderreuther S, von Maydell R, Straube A: A CPH-like picture in two
patients with an orbitocavernous sinus syndrome. Cephalalgia 1997,
17(5):608–611.
doi:10.1186/1471-2377-14-7
Cite this article as: Hung et al.: Painful ophthalmoplegia with normal
cranial imaging. BMC Neurology 2014 14:7.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
